Characterisation, cytotoxicity and apoptosis studies of methotrexate-loaded PLGA and PLGA-PEG nanoparticles

References

• Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Del Rev, 2002;54:631–51
   PubMed Web of Science ®Google Scholar
• Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. 2001. Antineoplastic agents. In: Hardmann JG, Limbird LE, Gilman AG, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill, pp. 1399–404
   Google Scholar
• Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbauma E, Radovic-Morenob AF, Langer R, Farokhzad OC. Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery. Biomaterials, 2007;28:869--76
   PubMed Web of Science ®Google Scholar
• Dadashzadeh S, Derakhshandeh K, HoseiniShirazi F. 9-Nitrocamptothecin polymeric nanoparticles: Cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats. Anti-Cancer Drugs, 2008;19:805–11
   PubMed Web of Science ®Google Scholar
• Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm, 2010;67(3):217–23
   PubMed Web of Science ®Google Scholar
• Derakhshandeh K, Erfan M, Dadashzadeh S. Encapsulation of 9- nitrocamptothecin, a novelanticancer drug, in biodegradable nanoparticles: Factorial design, characterization and release kinetics. Eur J Pharm Biopharm, 2007;66:34–41
   PubMed Web of Science ®Google Scholar
• Derakhshandeh K, Soheili M, Dadashzadeh S, Saghiri R. Preparation and in vitro characterization of 9-nitrocamptothecin loaded long circulating nanoparticles for delivery in cancer patients. Int J Nanomedicine, 2010;5:1–59
   PubMed Web of Science ®Google Scholar
• Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E, Rad-Malekshahi M, Atyabi F. Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomedicine: NBM, 2010;6:478–85
   PubMed Web of Science ®Google Scholar
• Ebrahimnejad P, Dinarvand R, Jafari MR, SajadiTabasi SA, Atyabi F. Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38. Int J Pharm, 2011;406:122–7
   PubMed Web of Science ®Google Scholar
• Esmaeili F, Ghahremani MH, Esmaeili B, Khoshayand MR, Atyabi F, Dinarvand R. PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distribution. Int J Pharm, 2008;349:249–55
   PubMed Web of Science ®Google Scholar
• Fernandez-Carballoido A, Pastoriza P, Barica E, Montejo C, Negro S. PLGA/PEG derivative polymeric matrix for drug delivery system application: Characterization and cell viability studies. Int J Pharm, 2008;352:50–7
   PubMedGoogle Scholar
• Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanism of action of methotrexate. Immuno Pharmacol, 2000;47:247–57
   PubMed Web of Science ®Google Scholar
• Harsh V, Bharat G, Vishnu A. Preparation and physicochemical characterization of methoteraxtae PLGA microparticles. Int J Pharm Res, 2010;2(1):75–81
   Google Scholar
• Holdenrieder S, Stiebe P. Apoptotic markers in cancer. Clin Biochem, 2004;37:605–17
   PubMed Web of Science ®Google Scholar
• Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release, 2007;118:7--17
   PubMed Web of Science ®Google Scholar
• Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Ravi Kumar MNV. PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to SandimmuneNeoral®. J Control Release, 2007;119:197–206
   PubMed Web of Science ®Google Scholar
• Kim SH, Jeong JH, Chun KW, Park TG. Target-specific cellular uptake of PLGA nanoparticles coated with poly(l-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir, 2005;21:8852–7
   PubMed Web of Science ®Google Scholar
• Kosasih A, Bowman BJ, Wigent RJ, Ofner III CM. Characterization and in vitro release of methotrexate from gelatin: Methotrexate conjugates formed using different preparation variables. Int J Pharm, 2000;204:81–9
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B: Biointerfaces, 2010;75:1–18
   PubMed Web of Science ®Google Scholar
• Mazur A, Nowak D, Mannherz HG, Malicka-Błaszkiewicz M. Methotrexate induces apoptosis in CaSki and NRK cells and influences the organization of their actin cytoskeleton. Eur J Pharmacol, 2009;613:24–33
   PubMed Web of Science ®Google Scholar
• Mashima T, Naito M, Tsuruo T. Caspase-mediated cleavage of cytoskeletal actin plays appositive role in the process of morphological apoptosis. Oncogene, 1999;18:2423–30
   PubMed Web of Science ®Google Scholar
• Mohammadi G, Nokhodchi A, Barzegar-Jalali M, Lotfipour F, Adibkia KH, Ehyaei N, Valizadeh H. Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system. Colloids Surf B: Biointerfaces, 2011;88:39–44
   PubMed Web of Science ®Google Scholar
• Müller RH. 1991. Charge determinations. In: Müller RH, ed. Colloidal carriers for controlled drug delivery and targeting modification, characterization and in vivo distribution. Boca Raton, FL: CRCPress, pp. 57–97
   Google Scholar
• Ofner CM, Pica K, Bowman BJ, Chen CS. Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates. Int J Pharm, 2006;308:90–9
   PubMed Web of Science ®Google Scholar
• Padmanabhan S, Tripathi DN, Vikram A, Ramarao P, Jena GB. Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: Intervention of folic and folinic acid. Mutat Res, 2009;673:43–52
   PubMed Web of Science ®Google Scholar
• Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, Fahmy TM. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine: NBM, 2009;5:410–18
   PubMed Web of Science ®Google Scholar
• Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res, 2000;45:528–37
   PubMed Web of Science ®Google Scholar
• Seo DH, Jeong YI, Kim DG, Jang MJ, Jang MK, Nah JW. Methotrexate-incorporated polymeric nanoparticles of methoxy poly (ethylene glycol)-grafted chitosan. Colloids Surf B: Biointerfaces, 2009;69:157–63
   PubMed Web of Science ®Google Scholar
• Singh R, Lillard JW, Jr. Nanoparticle-based targeted drug delivery. Experiment Mol Pathol, 2009;86:215–23
   PubMed Web of Science ®Google Scholar
• Taheri A, Atyabi F, Salman Nouri F, Ahadi F, Derakhshan MA, Amini M, Ghahremani H, Ostad SN, Mansoori P, Dinarvand R. Nanoparticles of conjugated methotrexate-human serum albumin: Preparation and cytotoxicity evaluations. J Nanomaterials, 2011;2011:1–7
   PubMed Web of Science ®Google Scholar
• Teixeira M, Alonso MJ, Pinto MM, Barbosa CM. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxy xanthone. Eur J Pharm Biopharm, 2005;59:491–500
   PubMed Web of Science ®Google Scholar
• Wyllie AH. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: An overview. Cancer Metastasis Rev, 1992;11:95–103
   PubMed Web of Science ®Google Scholar